N-3 LCPUFA Supplementation In Pregnancy To Reduce Allergies In Early Childhood
Funder
National Health and Medical Research Council
Funding Amount
$813,423.00
Summary
Over the last 20 years there has been a dramatic increase in allergic diseases in Australia as well as many other industrialised countries. This may be due to changes in our environment or diet. Over this period of time there has also been an increase in the dietary intake of n-6 fatty acids from vegetable oils and a corresponding decline in the intake of n-3 fatty acids from fish. Studies now indicate that there is a plausible link between these dietary changes and allergic diseases. Furthermor ....Over the last 20 years there has been a dramatic increase in allergic diseases in Australia as well as many other industrialised countries. This may be due to changes in our environment or diet. Over this period of time there has also been an increase in the dietary intake of n-6 fatty acids from vegetable oils and a corresponding decline in the intake of n-3 fatty acids from fish. Studies now indicate that there is a plausible link between these dietary changes and allergic diseases. Furthermore, emerging data suggest that the potential benefits of increasing n-3 fatty acids may be greatest during pregnancy and before allergic responses are established. Our project aims to minimise allergies in children from families where at least one parent has an allergy. We will assess whether dietary n-3 fatty acid supplementation of pregnant women will result in fewer children with allergies at 1 and 3 years of age. If the proposed intervention is successful, it would be a safe, cheap, acceptable and effective strategy to prevent allergies in children at high risk.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$1,477,963.00
Summary
Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a ....Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a normal protein in the blood, are another major causal risk factor for atherosclerosis (and stroke and heart attacks). Furthermore, blood concentrations of homocysteine can be lowered by about one quarter with simple, safe and inexpensive multivitamin therapy (folic acid, vitamin B12, and vitamin B6). However, despite the potentially massive public health benefits of such a strategy, it remains to be demonstrated in properly designed clinical trials that lowering homocysteine levels in the blood actually prevents stroke and heart attack. The VITATOPS trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$470,887.00
Summary
The VITAmins To Prevent Stroke (VITATOPS) trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke. To date more than 7,500 patients have been randomised. Ongoing support is requested to complete the follow-up of 8,000 patients by middle of 2009.
Antioxidants Vitamin C And Vitamin E For The Prevention Of Pre-eclampsia - A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$696,750.00
Summary
Women who develop hypertension in pregnancy have a higher risk of complications in pregnancy and their babies are often born smaller than average and earlier. An initial trial to women at high risk of pre-eclampsia suggest that vitamin C and vitmin E supplements may decrease both reduce the risk of developing hypertension in pregnancy and the risk of the infant being born small for dates. These encouraging results need assessment in the Australian population. This study assesses the value of wom ....Women who develop hypertension in pregnancy have a higher risk of complications in pregnancy and their babies are often born smaller than average and earlier. An initial trial to women at high risk of pre-eclampsia suggest that vitamin C and vitmin E supplements may decrease both reduce the risk of developing hypertension in pregnancy and the risk of the infant being born small for dates. These encouraging results need assessment in the Australian population. This study assesses the value of women taking vitamin C and vitamin E supplements during the antenatal period to decrease the risk of developing hypertension during pregnancy and poor fetal growth. Such an easy and inexpensive therapy, if effective, would be an important advance.Read moreRead less